Joy Knight

769 total citations
13 papers, 633 citations indexed

About

Joy Knight is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Joy Knight has authored 13 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Pathology and Forensic Medicine and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Joy Knight's work include Monoclonal and Polyclonal Antibodies Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Cell death mechanisms and regulation (3 papers). Joy Knight is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Cell death mechanisms and regulation (3 papers). Joy Knight collaborates with scholars based in United States, Slovakia and Canada. Joy Knight's co-authors include Francisco J. Hernandez‐Ilizaliturri, Myron S. Czuczman, George Deeb, Paul K. Wallace, Nishitha Reddy, Mark S. Roth, Scott H. Olejniczak, Joanna Groden, Andrew M. Lowy and Julie P. Deans and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Joy Knight

13 papers receiving 619 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joy Knight United States	8	290	288	247	181	154	13	633
Michael Voralia Canada	11	309 1.1×	268 0.9×	229 0.9×	263 1.5×	149 1.0×	25	681
Ka Lung Wu Belgium	14	232 0.8×	361 1.3×	287 1.2×	210 1.2×	76 0.5×	39	708
TW Mak Canada	9	290 1.0×	198 0.7×	144 0.6×	200 1.1×	292 1.9×	13	671
Magdalena Klánová Czechia	12	397 1.4×	346 1.2×	231 0.9×	252 1.4×	130 0.8×	38	721
Marie‐José Rapp France	6	287 1.0×	191 0.7×	289 1.2×	360 2.0×	159 1.0×	7	720
Aruna Gowda United States	8	263 0.9×	231 0.8×	87 0.4×	222 1.2×	186 1.2×	15	516
Gavin Babbage United Kingdom	6	254 0.9×	142 0.5×	109 0.4×	242 1.3×	154 1.0×	9	433
Eva Maria Murga Penas Germany	14	239 0.8×	247 0.9×	182 0.7×	196 1.1×	111 0.7×	31	550
Michael Pearson United States	4	518 1.8×	204 0.7×	147 0.6×	536 3.0×	361 2.3×	8	860
Lixia Pei United States	10	224 0.8×	312 1.1×	176 0.7×	144 0.8×	38 0.2×	27	476

Countries citing papers authored by Joy Knight

Since Specialization

Citations

This map shows the geographic impact of Joy Knight's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joy Knight with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joy Knight more than expected).

Fields of papers citing papers by Joy Knight

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joy Knight. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joy Knight. The network helps show where Joy Knight may publish in the future.

Co-authorship network of co-authors of Joy Knight

This figure shows the co-authorship network connecting the top 25 collaborators of Joy Knight. A scholar is included among the top collaborators of Joy Knight based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joy Knight. Joy Knight is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Brém, Elizabeth, Scott H. Olejniczak, Seema A. Bhat, et al.. (2011). Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas. British Journal of Haematology. 153(5). 599–611. 46 indexed citations

Czuczman, Myron S., Scott H. Olejniczak, Aruna Gowda, et al.. (2008). Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both GlobalCD20Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels. Clinical Cancer Research. 14(5). 1561–1570. 181 indexed citations

Hernandez‐Ilizaliturri, Francisco J., Scott H. Olejniczak, George Deeb, et al.. (2007). CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: Preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leukemia & lymphoma. 48(12). 2424–2436. 28 indexed citations

Reddy, Nishitha, Francisco J. Hernandez‐Ilizaliturri, George Deeb, et al.. (2007). Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo. British Journal of Haematology. 140(1). 36–45. 219 indexed citations

Hernandez‐Ilizaliturri, Francisco J., et al.. (2007). Augmented Antitumor Activity against B-Cell Lymphoma by a Combination of Monoclonal Antibodies Targeting TRAIL-R1 and CD20. Clinical Cancer Research. 13(15). 4556–4564. 47 indexed citations

Hernandez‐Ilizaliturri, Francisco J., et al.. (2007). Targeting BH3-Domain Anti-Apoptotic Proteins with ABT-737 Decreases DNA Synthesis, Induces Cell Death and Sensitizes Rituximab-Sensitive and Rituximab-Resistant Non-Hodgkin’s Lymphoma Cell Lines to the Anti-Tumor Activity of Chemotherapy Agents.. Blood. 110(11). 1393–1393. 1 indexed citations

Czuczman, Myron S., et al.. (2007). GX15-070 and Bortezomib Induce Up-Regulation of BH3 Single Domain Pro-Apoptotic Proteins Puma and Noxa and Is Associated with Synergistic Anti-Tumor Activity in Rituximab-Sensitive, Rituximab-Resistant Cell Lines (RSCL and RRCL), and Primary Lymphoma Patient Specimens.. Blood. 110(11). 1389–1389. 4 indexed citations

Hernandez‐Ilizaliturri, Francisco J., et al.. (2006). Impaired Ca++ mobilization in rituximab-resistant cells (RRCL) is associated with changes in the structure of CD20 antigen, down-regulation of Bax/Bak pro-apoptotic proteins and up-regulation of the endoplasmic reticulum (ER) Ca++ pump protein SERCA-3. Journal of Clinical Oncology. 24(18_suppl). 2516–2516. 3 indexed citations

Reddy, Nishitha, et al.. (2006). Lenalidomide (Revlimid®) Enhances Monoclonal Antibody-Associated Anti-Tumor Activity Against Rituximab-Sensitive and Rituximab-Resistant B-Cell Lymphoma Cell Lines.. Blood. 108(11). 2522–2522. 5 indexed citations

10.

Czuczman, Myron S., et al.. (2005). In Vitro Synergistic Anti-Tumor Activity by Targeting TRAIL-R1 and CD20 Antigen by Combining HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) and Rituximab Monoclonal Antibody Against Non-Hodgkin’s Lymphoma Cells (NHL).. Blood. 106(11). 1475–1475. 3 indexed citations

11.

Hernandez‐Ilizaliturri, Francisco J., et al.. (2005). Targeting CD20 and CD22 with Rituximab in Combination with CMC-544 Results in Improved Anti-Tumor Activity Against Non-Hodgkin’s Lymphoma (NHL) Pre-Clinical Models.. Blood. 106(11). 1473–1473. 7 indexed citations

12.

Lowy, Andrew M., Cecilia M. Fenoglio‐Preiser, On Ja Kim, et al.. (2003). Dysregulation of ?-Catenin Expression Correlates With Tumor Differentiation in Pancreatic Duct Adenocarcinoma. Annals of Surgical Oncology. 10(3). 284–290. 50 indexed citations

13.

Lowy, Andrew M., Joy Knight, & Joanna Groden. (2002). Restoration of E-cadherin/β-catenin expression in pancreatic cancer cells inhibits growth by induction of apoptosis. Surgery. 132(2). 141–148. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact